Oncolytic Virotherapy and the Tumor Microenvironment

Area of Science:

• Oncology
• Virology
• Immunotherapy

Background:

• Oncolytic viral therapy is an emerging cancer treatment strategy.
• Genetically modified viruses show promise for treating various cancers, including breast, colorectal, hepatocellular, and melanoma.

Purpose of the Study:

• To explore the mechanisms and potential of targeted and armed oncolytic viruses in cancer therapy.
• To highlight how these viruses can be engineered to selectively kill cancer cells and modify the tumor microenvironment.

Main Methods:

• Genetic modification of viruses to achieve selective replication in cancer cells.
• Engineering viruses to express transgenes that inhibit tumor progression and modulate the immune system.
• Investigating the virus's ability to induce anti-vascular effects and disrupt the extracellular matrix.

Main Results:

• Engineered oncolytic viruses selectively replicate within cancer cells, leading to tumor cell death.
• Transgene products from armed viruses induce cell death, reduce viral virulence, and compromise tumor vascularity.
• Oncolytic viruses enhance immune responses through cytokines and chemokines, improve tumor cell death, and disrupt the tumor microenvironment.

Conclusions:

• Targeted and armed oncolytic viruses represent a potent therapeutic strategy for multiple malignancies.
• These viruses offer a multi-pronged approach by directly killing cancer cells, enhancing anti-tumor immunity, and disrupting the tumor's supportive environment.
• Further development of oncolytic viral therapy holds significant promise for improving cancer treatment outcomes.